Clinical trial
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With…
NCT00810693 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00810693 |
|---|---|
| Title | A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) |
| Official title | Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) |
| Acronym | PATENT-1 |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Riociguat (Adempas, BAY63-2521), Placebo |
| Enrollment | 445 |
| Start date | Dec 17, 2008 |
| Primary completion | May 14, 2012 |
| Completion | May 14, 2012 |
| First posted | Dec 18, 2008 |
| Last update posted | Nov 22, 2023 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece and 18 more |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: